drugset / Trial / NCT00058123

Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma

NCT00058123

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Biological therapies such as poly-ICLC use different ways to stimulate the immune system and stop tumor cells from growing. PURPOSE: This phase II trial is studying how poly-ICLC works in treating patients with recurrent, progressive, or relapsed anaplastic glioma.

Timeline

Start
2003-03-07
Primary completion
2007-10-06
Completion
2009-01-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Hiltonol Other / unclassified 20 ug/kg Intramuscular